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CoV-2: Can we shorten 
incubation times without 
compromising results?
To the Editor: The first COVID-19 case in 
South Africa was reported on 5 March 2020, 
with a lockdown period implemented within 
the same month. The second wave of COVID-
19 started on 12 November in Western Cape 
Province. Currently the country is in the third 
wave. The increase in febrile patients during 
the spread of SARS-CoV-2 resulted in an 
increase in blood cultures (BCs) submitted 
to our diagnostic laboratory (National Health 
Laboratory Service, Groote Schuur Hospital) 
for processing. The value of a BC to direct 
therapy and identify a disease-causing 
pathogen is widely appreciated. However, 
little is known of its usefulness in COVID-
19 confirmed cases, and the evidence 
suggests a low incidence of co-infections with 
bacteraemia.[1-3] These surges in BC requests 
during COVID-19 peaks have the potential 
to overwhelm resource-limited laboratories 
that have limited space in their automated 
BC incubation instruments. Delaying the 
time to incubation of newly received bottles 
may delay the identification of pathogens as 
well as decrease the diagnostic yield. These 
factors can impact negatively on clinician 
antimicrobial treatment decisions, and from 
an antimicrobial stewardship stance may lead 
to missed opportunities to de-escalate or stop 
antimicrobials.[4] To mitigate this problem 
in future, it is worth exploring whether 
incubation times can be shortened, thereby 
freeing up incubator space more quickly.
The objective of this study was to 
determine the proportion of positive BCs 
that were processed over a 6-month period 
prior to and during the first wave of the 
COVID-19 pandemic; the incubation time 
to positivity; and the organisms identified 
from those BCs that only flagged positive 
on day 5 of incubation. We retrospectively 
analysed BCs submitted from various 
healthcare institutions to the National Health 
Laboratory Service at Groote Schuur Hospital 
from 1 January 2020 to 30 June 2020. Ethical 
and institutional approval for the study was 
obtained (ref. no. HREC 714/2020).
Of 22 156 BCs collected over 6 months, 
3 228 (14.6%) had a micro-organism cultured. 
Of these positive cultures, 1  109 (34.4%) were 
probable contaminants (coagulase-negative 
staphylococci, Cutibacterium spp., Micrococcus 
spp., Bacillus spp., Corynebacterium spp., 
Aerococcus spp. and Viridans streptococci). Most 
of the pathogenic bacteria cultured belonged to 
the Enterobacterales order (Fig. 1A). The mean 
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Fig. 1. (A) Blood cultures submitted to Groote Schuur Hospital National Health Laboratory Service 
between 1 January 2020 and 30 June 2020, with the 20 most prevalent pathogenic organisms cultured. 
(B) Percentage of blood cultures that signalled positive on days 1 - 5. (C) Micro-organisms cultured on 
day 5, with the red bars indicating potential skin flora contaminants.
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number of BCs sent to the laboratory during May and June increased by 
14% compared with the previous 2 months and exceeded our automated 
instrument testing capacity. Most BCs (91.8%) signalled positive within 
the first 48 hours of incubation between 1 January 2020 and 30 June 2020 
(Fig. 1B). Only 40 (1.2%) of the positive BCs submitted cultured a micro-
organism on day 5 (Fig. 1C), mainly with bacteria deemed contaminants 
(70.0%). The low yield of positive BCs during day 5 may justify a 
shorter period of incubation during peak times.[5] The exceptions 
to a shortened incubation duration are a suspicion of or proven 
fungaemia; specific clinical scenarios, e.g. infective endocarditis, 
that are known to be caused by fastidious organisms; and known 
Staphylococcus aureus bacteraemia, because missing this can have 
serious health consequences.[5]
It has been recommended that empirical antibiotics are withheld in 
the absence of compelling evidence of bacterial co-infection in a patient 
with COVID-19.[6] Reducing BC requests coupled with decreasing 
incubation times of BCs may preserve operational capacities during 
subsequent COVID-19 peaks. The rationale for increased BCs during 
the COVID-19 pandemic was not determined, but it may be that 
clinicians overestimated the frequency of co-infection or lacked the 
confidence to exclude co-infection on clinical presentation alone. In 
conclusion, the yield of positive BCs on day 5 remained low, with 
only 1.2% of cultures flagging positive; 70.0% (n=28/40) of these 
are likely to have been contaminants. It is therefore reasonable to 
shorten standard incubation periods when testing demand increases. 
Clinicians should provide clinical information on the laboratory 
request forms so that it can be determined whether a patient falls into 
an ‘exception category’ that justifies a standard incubation duration 
over a shortened one. BCs with no growth after day 3 are unlikely to 
become positive, and clinicians should consider this when consulted 
on patient management.
C J Opperman, N Samodien
Division of Medical Microbiology, National Health Laboratory Service, 
University of Cape Town and Groote Schuur Hospital, Cape Town, 
South Africa
stefanopperman1@gmail.com
1. Engsbro AL, Israelsen SB, Pedersen M, et al. Predominance of hospital-acquired bloodstream infection 
in patients with Covid-19 pneumonia. J Infect 2020;52(12):919-922. https://doi.org/10.1080/23744235.2
020.1802062
2. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with 
COVID-19: A living rapid review and meta-analysis. Clin Microbiol Infect 2020; 26(12):1622-1629. 
https://doi.org/10.1016/j.cmi.2020.07.016
3. Lansbury L, Lim B, Baskaran V, et al. Co-infections in people with COVID-19: A systematic review and 
meta-analysis. J Infect 2020;81(2):266-275. https://doi.org/10.2139/ssrn.3594598
4. Ling CL, Roberts T, Soeng S, et al. Impact of delays to incubation and storage temperature on blood culture 
results: A multi-centre study. BMC Infect Dis 2021;21:173 https://doi.org/10.1186/s12879-021-05872-8
5. Bourbeau PP, Foltzer M. Routine incubation of BacT/ALERT FA and FN blood culture bottles for more 
than 3 days may not be necessary. J Clin Microbiol 2005;43(5):2506-2509. https://doi.org/10.1128/
JCM.43.5.2506-2509.2005
6. Sepulveda J, Westblade LF, Whittier S, et al. Bacteremia and blood culture utilization during COVID-19 
surge in New York City. J Clin Microbiol. 2020;58(8):e00875-20. https://doi.org/10.1128/JCM.00875-20
S Afr Med J 2021;111(9):814-815. https://doi.org/10.7196/SAMJ.2021.v111i9.15819
